Normal Testosterone & Erectile Function
Adequate testosterone supports libido and healthy erectile signaling.
- 300–1000: Normal serum testosterone (ng/dL typical adult range)
- ~90%: NOS expression baseline (healthy endothelial enzyme levels)
- 8–10/10: Libido score baseline (normal sexual desire)
- >90%: PDE5 inhibitor response (normal drug responsiveness)
Testosterone drives desire
Testosterone activates brain centers that generate sexual desire.
NOS keeps vessels ready
Nitric oxide synthase primes penile blood vessels for erection.
Testosterone above 300 ng/dL usually preserves normal erectile function.
A cooperating hormone-nerve-vessel axis
Hormones, nerves, and vessels cooperate smoothly in healthy men.
Testosterone Decline With Age Or Disease
Serum testosterone falls with aging, obesity, or illness.
- ~1%/yr: Testosterone drop after 30 (gradual age-related decline)
- ~40%: Hypogonadism prevalence (men over 45 affected)
- Obesity, diabetes: Common causes (metabolic disease links)
- <300: Symptom onset threshold (ng/dL clinical low-T cutoff)
A gradual hormonal slide
Testosterone declines gradually after age thirty.
Metabolic disease accelerates decline
Obesity and diabetes accelerate testosterone loss.
Low testosterone is common but frequently overlooked in clinic.
An underdiagnosed condition
Low testosterone often goes undiagnosed for years.
Reduced Nitric Oxide Synthase Expression
Low testosterone lowers NOS gene expression in penile tissue.
- ~30%: NOS expression decline (testosterone-dependent suppression)
- Androgen-responsive: eNOS gene regulation (testosterone controls transcription)
- Impaired: Endothelial function (reduced vessel responsiveness)
- Possible: Recovery with therapy (reversible with treatment)
Testosterone switches on NOS
Testosterone normally switches on the NOS gene.
Silenced transcription
Low androgen levels silence NOS transcription.
NOS expression tracks serum testosterone levels closely.
Less enzyme, less signal
Endothelial cells produce less nitric oxide enzyme.
Impaired Nitric Oxide Pathway
Less nitric oxide reaches smooth muscle for relaxation.
- Reduced: Baseline NO availability (less vasodilator signal)
- Diminished: cGMP production (weaker smooth muscle relaxation)
- Reduced: Cavernosal blood flow (impaired tissue engorgement)
- Decreased: Erection rigidity (functional consequence)
Nitric oxide relaxes muscle
Nitric oxide relaxes smooth muscle for erection.
Less enzyme, less nitric oxide
Less NOS means less nitric oxide produced.
The NO-cGMP pathway depends on adequate testosterone.
Weak vasodilation limits flow
Weak vasodilation limits blood flow into tissue.
Reduced PDE5 Inhibitor Responsiveness
Low testosterone blunts response to PDE5 inhibitors alone.
- Reduced: PDE5i response in low-T men (lower success rates)
- Improved: Combination therapy benefit (TRT plus PDE5i)
- Testosterone-dependent: NOS substrate requirement (enzyme needs hormone support)
- Restore T first: Treatment strategy (clinical recommendation)
Drugs need a baseline signal
PDE5 inhibitors need baseline nitric oxide production.
Too little to amplify
Low testosterone leaves too little NO to amplify.
Combining testosterone therapy with PDE5 inhibitors often helps most.
Restoring hormone restores response
Restoring testosterone can restore drug responsiveness.